Hyloris Pharmaceuticals SA (EBR:HYL)

Market Cap	104.16M -39.0%
Revenue (ttm)	9.83M +16.2%
Net Income	-4.65M
EPS	-0.17
Shares Out	28.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,529
Open	3.950
Previous Close	3.950
Day's Range	3.680 - 3.950
52-Week Range	3.680 - 8.400
Beta	0.64
Analysts	Buy
Price Target	11.23 (+201.88%)
Earnings Date	Sep 24, 2026

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Ato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 54
• Stock Exchange: Euronext Brussels
• Ticker Symbol: HYL

Financial Performance

In 2025, Hyloris Pharmaceuticals's revenue was 7.94 million, a decrease of -18.66% compared to the previous year's 9.76 million. Losses were -6.33 million, -0.13% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for HYL stock is "Buy." The 12-month stock price target is €11.23, which is an increase of 201.88% from the latest price.

Price Target

€11.23

(201.88% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error